MA33292B1 - Production de nanoparticules encapsulees a des fins commerciales - Google Patents

Production de nanoparticules encapsulees a des fins commerciales

Info

Publication number
MA33292B1
MA33292B1 MA34378A MA34378A MA33292B1 MA 33292 B1 MA33292 B1 MA 33292B1 MA 34378 A MA34378 A MA 34378A MA 34378 A MA34378 A MA 34378A MA 33292 B1 MA33292 B1 MA 33292B1
Authority
MA
Morocco
Prior art keywords
production
biologically active
commercial purposes
nanoparticles encapsulated
compositions
Prior art date
Application number
MA34378A
Other languages
Arabic (ar)
English (en)
Inventor
Aaron Dodd
Felix Meiser
Adrian Russell
Marck Norret
H William Bosch
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901740A external-priority patent/AU2009901740A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of MA33292B1 publication Critical patent/MA33292B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/10—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls with one or a few disintegrating members arranged in the container
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/34—Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N39/00—Biocides, pest repellants or attractants, or plant growth regulators containing aryloxy- or arylthio-aliphatic or cycloaliphatic compounds, containing the group or, e.g. phenoxyethylamine, phenylthio-acetonitrile, phenoxyacetone
    • A01N39/02—Aryloxy-carboxylic acids; Derivatives thereof
    • A01N39/04—Aryloxy-acetic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/10—Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
    • A01N57/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds
    • A01N57/20—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds containing acyclic or cycloaliphatic radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La présente invention concerne des procédés de production de particules d'une matière biologiquement active au moyen de processus de broyage à sec ainsi que des compositions comprenant de telles matières, des médicaments produits au moyen desdites matières biologiquement actives sous forme particulaire et/ou des compositions, et concerne également des méthodes de traitement d'un animal, y compris l'homme, au moyen d'une quantité thérapeutiquement efficace desdites matières biologiquement actives administrées à l'aide desdits médicaments.
MA34378A 2009-04-24 2010-04-23 Production de nanoparticules encapsulees a des fins commerciales MA33292B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17229709P 2009-04-24 2009-04-24
AU2009901740A AU2009901740A0 (en) 2009-04-24 Production of Encapsulated nanoparticles at Commercial Scale
PCT/AU2010/000466 WO2010121322A1 (fr) 2009-04-24 2010-04-23 Production de nanoparticules encapsulées à des fins commerciales

Publications (1)

Publication Number Publication Date
MA33292B1 true MA33292B1 (fr) 2012-05-02

Family

ID=43010605

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34378A MA33292B1 (fr) 2009-04-24 2010-04-23 Production de nanoparticules encapsulees a des fins commerciales

Country Status (21)

Country Link
US (6) US20120202694A1 (fr)
EP (1) EP2421510B1 (fr)
JP (3) JP6141013B2 (fr)
KR (4) KR20160148041A (fr)
CN (3) CN102740835A (fr)
AP (1) AP3776A (fr)
AU (1) AU2010239161B2 (fr)
BR (1) BRPI1014276B8 (fr)
CA (1) CA2759108C (fr)
CO (1) CO6470811A2 (fr)
EA (1) EA201171281A1 (fr)
IL (2) IL254371B2 (fr)
MA (1) MA33292B1 (fr)
MX (1) MX359793B (fr)
MY (1) MY177537A (fr)
NZ (1) NZ595984A (fr)
PH (1) PH12015501780A1 (fr)
SG (3) SG10201401705VA (fr)
UA (1) UA111138C2 (fr)
WO (1) WO2010121322A1 (fr)
ZA (1) ZA201108649B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000042A1 (fr) 2006-06-30 2008-01-03 Iceutica Pty Ltd Procédés de préparation de composés biologiquement actifs sous forme de nanoparticules
US20120263760A1 (en) * 2009-04-24 2012-10-18 Aaron Dodd Novel formulation of metaxalone
IL254370B2 (en) * 2009-04-24 2023-12-01 Iceutica Pty Ltd Production of coated nanoparticles with a high particle volume
US20120148634A1 (en) * 2009-04-24 2012-06-14 Aaron Dodd Novel formulation of naproxen
NZ595986A (en) 2009-04-24 2014-04-30 Iceutica Pty Ltd A novel formulation of indomethacin
WO2013108061A1 (fr) * 2012-01-20 2013-07-25 NATUR FEED S.r.l. Adjuvant technologique destiné aux denrées fourragères et aux compléments de l'élevage et de la reproduction zootechniques
WO2014145813A1 (fr) * 2013-03-15 2014-09-18 Iceutica Inc. Formulation d'acétate d'abiratérone
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
CN104887633B (zh) * 2014-03-04 2019-01-29 山东新时代药业有限公司 一种利伐沙班片剂及其制备方法
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN104042502B (zh) * 2014-06-10 2016-04-27 刘佰岭 一种深层渗透吸收并促进新陈代谢延缓衰老的护肤组合物
TN2017000098A1 (en) * 2014-09-18 2018-10-19 Iceutica Inc Abiraterone acetate formulation and methods of use.
US9480656B1 (en) 2015-09-28 2016-11-01 King Saud University Method of preparing rosemary nanoparticles and encapsulated rosemary nanoparticles
US9730867B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Methods of forming a slurry with microcapsules formed from phosphate esters
US10154947B2 (en) 2016-01-06 2018-12-18 The Procter & Gamble Company Antiperspirant composition
US9732303B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Microcapsules formed from phosphate esters and compositions containing same
CN108882729A (zh) * 2016-03-25 2018-11-23 安迪苏法国联合股份有限公司 脂溶性活性成分的纳米胶囊，其制造和用途
CN109640947A (zh) 2016-08-05 2019-04-16 株式会社新日本科学 鼻内药物粉末组合物
JP6967715B2 (ja) * 2017-04-18 2021-11-17 パナソニックＩｐマネジメント株式会社 カメラ校正方法、カメラ校正プログラム及びカメラ校正装置
WO2019009335A1 (fr) * 2017-07-04 2019-01-10 村上　正裕 Procédé de production de particules fines et particules fines
CN108439978A (zh) * 2018-05-07 2018-08-24 内蒙古科技大学 一种氧化钇稳定氧化锆粉体及其制备方法和陶瓷
CN109481739B (zh) * 2018-12-12 2021-07-30 四川大学华西医院 一种骨关节润滑剂及其制备方法
US11891588B2 (en) 2019-07-31 2024-02-06 Ecolab Usa Inc. Personal protective equipment free delimer compositions o
CN113133970A (zh) * 2020-01-17 2021-07-20 美国琛蓝营养制品股份有限公司 一种姜黄素复合物及其制备方法和检测方法
WO2023049420A1 (fr) * 2021-09-24 2023-03-30 Donaldson Chadwick Formulations moussantes de poudre sèche pour l'administration de médicaments à travers la muqueuse
CN116409779A (zh) * 2021-12-30 2023-07-11 南方科技大学 一种微纳米碳颗粒及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61148114A (ja) * 1984-11-15 1986-07-05 Teijin Ltd ニフエジピンの顆粒剤
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5955143A (en) * 1995-12-21 1999-09-21 Drexel University Hollow polymer microcapsules and method of producing the same
JP4117811B2 (ja) * 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
ATE378039T1 (de) * 2000-06-27 2007-11-15 Vectura Ltd Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung
DE60137943D1 (de) 2000-08-31 2009-04-23 Jagotec Ag Gemahlene partikel
EP2283818B1 (fr) * 2000-11-30 2017-08-02 Vectura Limited Procede de preparation de particules destinees a etre utilisees dans une composition pharmaceutique
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
ES2206066B1 (es) * 2002-10-28 2005-05-01 Universidad Politecnica De Valencia Transposicion de beckmann de la oxima de la ciclododecanona con catalizadores solidos.
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
NZ555719A (en) * 2004-12-31 2010-11-26 Iceutica Pty Ltd Nanoparticle composition and methods for synthesis thereof
BRPI0611075A2 (pt) * 2005-06-03 2010-08-03 Elan Pharma Int Ltd formulações de acetaminofeno em nanopartìcula
WO2007070851A2 (fr) * 2005-12-15 2007-06-21 Acusphere, Inc. Procedes d'elaboration de preparations pharmaceutiques a base de particules pour administration pulmonaire ou nasale
ES2334164T3 (es) * 2005-12-15 2010-03-05 Acusphere, Inc. Procedimiento de preparacion de formulaciones farmaceuticas a base de particulas para administracion parenteral.
JP2007169226A (ja) * 2005-12-22 2007-07-05 Ono Pharmaceut Co Ltd 固体分散体
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
WO2008000042A1 (fr) * 2006-06-30 2008-01-03 Iceutica Pty Ltd Procédés de préparation de composés biologiquement actifs sous forme de nanoparticules
NZ573823A (en) * 2006-06-30 2012-05-25 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
WO2008143239A1 (fr) * 2007-05-21 2008-11-27 Toray Industries, Inc. Particules de micropoudre cristalline
JP4789901B2 (ja) * 2007-10-02 2011-10-12 横浜油脂工業株式会社 水分散性粉末状遊離型植物ステロール組成物、及び、該組成物を配合した飲食品
US8568696B2 (en) * 2008-08-06 2013-10-29 Indiana Nanotech Llc Grinding method for the manipulation or preservation of calcium phosphate hybrid properties
US9684770B2 (en) * 2008-10-22 2017-06-20 Koninklijke Philips N.V. Performing measurement of a subject
US20120263760A1 (en) * 2009-04-24 2012-10-18 Aaron Dodd Novel formulation of metaxalone
BRPI1014272A2 (pt) * 2009-04-24 2016-10-18 Iceutica Pty Ltd nova formulação de diclofenac
IL254370B2 (en) * 2009-04-24 2023-12-01 Iceutica Pty Ltd Production of coated nanoparticles with a high particle volume
US20120148634A1 (en) * 2009-04-24 2012-06-14 Aaron Dodd Novel formulation of naproxen
JP5898613B2 (ja) * 2009-04-24 2016-04-06 イシューティカ ピーティーワイ リミテッド 生物学的活性物質の溶解プロファイルを改善するための方法
JP5906181B2 (ja) * 2009-04-24 2016-04-20 イシューティカ ピーティーワイ リミテッド 商業的ナノ粒子及びマイクロ粒子粉末の生産方法
NZ595986A (en) * 2009-04-24 2014-04-30 Iceutica Pty Ltd A novel formulation of indomethacin
EP2421540B1 (fr) * 2009-04-24 2017-12-27 Iceutica Pty Ltd. Nouvelle formulation de méloxicam

Also Published As

Publication number Publication date
SG175765A1 (en) 2011-12-29
BRPI1014276B1 (pt) 2020-06-30
US20210260598A1 (en) 2021-08-26
US20190193085A1 (en) 2019-06-27
JP2015155424A (ja) 2015-08-27
CA2759108C (fr) 2020-05-05
IL215866A0 (en) 2012-01-31
MX359793B (es) 2018-10-08
IL254371A0 (en) 2017-11-30
IL254371B2 (en) 2023-09-01
SG10201401705VA (en) 2014-08-28
PH12015501780A1 (en) 2017-07-31
AP3776A (en) 2016-08-31
JP2017081983A (ja) 2017-05-18
US20230356232A1 (en) 2023-11-09
MY177537A (en) 2020-09-17
US20120202694A1 (en) 2012-08-09
CN107049957A (zh) 2017-08-18
JP6141013B2 (ja) 2017-06-07
MX2011011218A (es) 2012-02-08
CN105919939A (zh) 2016-09-07
KR20160148041A (ko) 2016-12-23
UA111138C2 (uk) 2016-04-11
US20180169662A1 (en) 2018-06-21
CO6470811A2 (es) 2012-06-29
EA201171281A1 (ru) 2012-05-30
CN102740835A (zh) 2012-10-17
ZA201108649B (en) 2013-01-30
KR20180014238A (ko) 2018-02-07
EP2421510A4 (fr) 2013-01-09
EP2421510A1 (fr) 2012-02-29
JP2012524718A (ja) 2012-10-18
KR20150038704A (ko) 2015-04-08
AP2011005996A0 (en) 2011-12-31
BRPI1014276B8 (pt) 2021-05-25
WO2010121322A1 (fr) 2010-10-28
KR20120088546A (ko) 2012-08-08
AU2010239161B2 (en) 2014-10-09
BRPI1014276A2 (pt) 2016-10-18
AU2010239161A1 (en) 2011-11-10
IL254371B1 (en) 2023-05-01
EP2421510B1 (fr) 2019-07-31
US20150209796A1 (en) 2015-07-30
NZ595984A (en) 2014-04-30
SG10201607849TA (en) 2016-11-29
JP6175464B2 (ja) 2017-08-02
KR101979164B1 (ko) 2019-05-15
CA2759108A1 (fr) 2010-10-28

Similar Documents

Publication Publication Date Title
MA33292B1 (fr) Production de nanoparticules encapsulees a des fins commerciales
MA33297B1 (fr) Production de nanoparticules encapsulées à des fractions volumiques élevées
MA33294B1 (fr) Procédé destiné à la production de poudres de nanoparticules et de microparticules à usage commercial
MA33299B1 (fr) Nouvelle formulation de naproxène
MA33296B1 (fr) Nouvelle formulation d&#39;indométhacine
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA35567B1 (fr) Nouvelle formulation de méloxicam
Kowalczyk et al. All that glitters is not silver—a new look at microbiological and medical applications of silver nanoparticles
NZ595903A (en) A novel formulation of metaxalone
PH12015501811A1 (en) Production of encapsulated nanoparticles at high volume fractions
AU2014208310B2 (en) A Novel Formulation of Diclofenac
NZ710321A (en) Production of encapsulated nanoparticles at high volume fractions
TH140026A (th) สูตรตำรับใหม่ของอินโดเมธาซิน
TH140027A (th) สูตรตำรับใหม่ของไดโคลฟีแนค
NZ710322A (en) A novel formulation of metaxalone